(Q34782022)

4 August 2017

1 reference

title

The clinical use of bone resorption markers in patients with malignant bone disease (English)

1 reference

4 August 2017

0 references

Robert E Coleman

1

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 May 2002

1 reference

4 August 2017

1 reference

4 August 2017

volume

94

1 reference

4 August 2017

issue

10

1 reference

4 August 2017

page(s)

2521-2533

1 reference

The clinical course of bone metastases from breast cancer

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Bone densitometry in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Metabolic effects of pamidronate in patients with metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Biochemical prediction of response of bone metastases to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Bone markers in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Total urinary and free serum hydroxyproline in metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Urinary pyridinium crosslinks of collagen: specific markers of bone resorption in metabolic bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Measurement of urinary collagen cross-links indicate response to therapy in patients with breast cancer and bone metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Biochemical markers of bone metabolism: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Ectopic expression of bone sialoprotein in human thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Expression of bone sialoprotein in primary human breast cancer is associated with poor survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Markers of bone turnover for the management of patients with bone metastases from prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Markers of bone turnover in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

7 January 2021

Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

7 January 2021

Bisphosphonates as anticancer drugs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

7 January 2021

Reduction in new metastases in breast cancer with adjuvant clodronate treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

7 January 2021

Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

7 January 2021

Novel Serum Markers of Bone Resorption: Clinical Assessment and Comparison with Established Urinary Indices

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

7 January 2021

Markers of bone resorption in patients treated with pamidronate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

7 January 2021

Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

7 January 2021

Diagnostic validity of bone metabolic markers for bone metastasis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

7 January 2021

Relation between serum and urinary calcium with particular reference to parathyroid activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

7 January 2021

Calcium excretion (CaE) in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

7 January 2021

Estimation of whole body bone resorption rate: A comparison of urinary total hydroxyproline excretion with two radioisotopic tracer methods in osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

7 January 2021

The clinical measurement of urinary total hydroxyproline excretion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

7 January 2021

The response evaluation of bone metastases in mammary carcinoma. The value of radiology, scintigraphy, and biochemical markers of bone metabolism

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

7 January 2021

Assessment of response of bone metastases to systemic treatment in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

7 January 2021

A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

7 January 2021

Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

7 January 2021

Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

7 January 2021

Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

7 January 2021

Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

7 January 2021

Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

7 January 2021

Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10522

7 January 2021

Identifiers

DOI

10.1002/CNCR.10522

1 reference

4 August 2017

1 reference